Bpifrance is a financial institution dedicated to supporting companies throughout their development stages, particularly those preparing for stock market listing and seeking credit equity. The organization provides a range of financial solutions, including financing, innovation assistance, and capital investment. By integrating various entities such as OSEO and CDC Entreprises, Bpifrance aims to deliver tailored financial support that addresses the specific needs of businesses. The institution is committed to fostering innovation and helping companies transition toward sustainable growth, ensuring they are well-equipped to face future challenges.
Director of Transverse Venture Capital Investments Division
Benoit Barteau Ph.D
Investment Director
Nicolas Berdou
Investment Director, Defense Expert
Clarisse Blandin
Investment Director
Elyssa Maufras du Châtellier
Investment Director
Edouard Combette
Investment Director
Charlotte Corbaz
Investment Drector - Large Venture
Sofia Dahoune
Associate
Nicolas Dardenne
Senior Investment Director, Normandy (Caen Rouen)
Arnaud Despoisse
Director of Occitanie Participations
Nicolas Dufourcq
CEO
Mailys Ferrere
Director of Large Venture Investments
Romain Fourcade
Investment Director
Paul-Francois Fournier
Executive Director, Innovation Department
Vanessa Giraud
Director of Environmental Impact Funds
Alessandro Gonella
Director
Gwenael Hamon
Investment Director
Laurent Higueret
Senior Investment Director, Healthcare and Life Sciences - Large Venture Fund
Veronique Jacq
Head of Digital Venture team
Louis Janneau
Investment Director and Fund Manager
Magali Joessel
Director of Funds
So-Yeon Koo
Senior Investment Manager
Jérôme Langlade
Investment Director Aquitaine / Limousin / Poitou-Charentes
Eric Lefebvre
Director
Stephane Lefevre-Sauli
Senior Investment Director
Arnaud Legardeur
Investment Director
Olivier Martinez
Investment Director
Serge Mesguich
Director of FIT
Louis Molis
Investment Director
Jean-Francois Morin
Investment Director
Sébastien Moynot
Director
Adrien Muller
Investment Director
Adrien Neel
Investment Director
Axel Piriou
Director of Investments
Olivier Rameil
Senior Investment Director / VC seed
Vincent Roque
Director
Thibaut Roulon Ph.D
Investment Director
Gilles Schang
Deputy Managing Director
Bruno Villeneuve
Associate
Jean-Marie Fougeray
Senior Investment Director, Brittany
Laure Michel
Investment Director
Past deals in Early Venture Stage
Versant
Grant in 2025
Tech solution to accelerate biodiversity restoration.
Mabqi
Grant in 2025
Mabqi is a fully integrated immunotherapy biopharmaceutical company.
The QA Company
Series A in 2025
The QA Company is an AI platform that boosts productivity by optimizing knowledge management and supporting decision-making.
HEXANA
Grant in 2025
HEXANA is an energy platform that combines flexible sodium-cooled fast neutron reactors with a thermal management system.
NEBULA
Grant in 2024
NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.
GAiF Ai
Series A in 2024
GAiF Ai is an online community driving Africa's generative AI revolution.
Hub2.Io
Series A in 2024
Hub2.Io is a system for digitizing ongoing transactions. Services like cash out, to pay, manage, and others are offered by them. Connecting businesses to their infrastructure will enable them to accept and process payments quickly and safely.
Lingua Custodia
Grant in 2024
Lingua Custodia SAS is a Fintech company specializing in machine translation solutions tailored for the financial sector. Founded in 2011 and headquartered in Montigny-le-Bretonneux, France, the company initially focused on providing specialized machine translation services. It has since expanded its offerings to include a suite of Natural Language Processing (NLP) applications, such as Speech-to-Text automation, document classification, and data extraction from unstructured documents. Lingua Custodia's platform supports various document types, including fund prospectuses, annual reports, and equity research, enabling financial professionals to streamline their translation processes. The company serves a diverse clientele, including investment houses, banks, and language service providers, delivering superior quality through advanced machine learning algorithms specifically designed for the financial domain. Its innovative technology has received recognition and awards within the industry, underscoring its commitment to enhancing translation efficiency for finance-related documents.
Meiogenix
Series A in 2024
Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.
Interactive Autonomous DYnamic Systems
Grant in 2024
Iadys designs, develops, and delivers robotic and AI innovations aimed at environmental preservation. The company's flagship product, the Jellyfishbot, is a robot that collects floating waste and oil in water bodies and performs underwater measurements. Iadys also offers the Mobile Oil Skimmer, which is used for oil spill response. These products are designed to access and clean hard-to-reach areas, contributing to cleaner and safer aquatic environments.
Beyond Aero
Series A in 2024
Beyond EFB is an innovative ecosystem of services and tools focused on meeting the needs of aviation. We offer assistance to pilots at every stage of their journey, from planning and document management to aircraft services quoting and booking. We are determined to drive the success of the aviation industry. Our platform is ready to transform how pilots operate, how companies engage with their customers and how the sector thrives. With our platform, pilots enjoy a seamless and integrated solution, simplifying their routines, increasing efficiency and enhancing their overall flight experience. And we go beyond: we track trends and create detailed profiles of service consumption and flight operations, generating valuable insights for industry companies to personalize their services, maximize sales opportunities, reduce operational costs and offer an exceptional experience to their customers. At Beyond EFB, we are not only committed to revolutionizing the aviation industry, but also to mitigate the environmental impact of flights. Through strategic partnerships and proprietary technology, Beyond EFB empowers airlines and pilots to take meaningful action in the fight against climate change, allowing them to easily calculate and offset their carbon emissions and take the operations closer to their global sustainability goals.
Kriptown
Series A in 2024
Kriptown is a financial platform that focuses on financing the development of regional startups and small to medium-sized enterprises (SMEs). It offers a unique opportunity for investors to purchase tokens linked to the value of a company's shares, thereby democratizing access to fundraising. By utilizing advanced technology and a creative strategy, Kriptown streamlines equity funding through a transparent process that includes standardized whitepapers for each investment opportunity. This ensures that investors have comprehensive information before making any commitments. Additionally, members can contribute digital assets, which may be stored, utilized, or exchanged on Kriptown's secondary market. The company emphasizes customer satisfaction and innovation, making investment in startups more accessible to a broad and diverse range of investors.
Hepta Medical
Series A in 2024
HEPTA Medical is a medical technology company focused on developing a microwave ablation platform for the treatment of early lung cancer. The company's innovative solution includes a microwave ablation catheter equipped with a proprietary temperature sensor, which allows healthcare professionals to monitor and control the ablation volume in real-time. This technology aims to provide a minimally invasive, nonsurgical treatment option, enhancing the efficiency and safety of cancer ablation procedures. By enabling precise control over the size of the lesion being treated, HEPTA Medical seeks to improve patient outcomes in cancer care.
Yumgo
Series A in 2024
Yumgo is a startup focused on creating plant-based egg alternatives designed for baking and cooking. The company develops both white and yellow egg substitutes using natural vegetable proteins, ensuring that the products are free from allergens. Yumgo aims to facilitate a shift toward sustainable dietary choices by offering flavorful options that allow consumers to maintain healthy eating habits without sacrificing taste.
Ray studios
Series A in 2024
Ray Studios is a Tattoo removal studio that employs hydraulic acoustic wave technology in its "Le Ray Spark" Tattoo removal treatment device.
Genomines
Grant in 2024
Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.
Continuity
Series A in 2024
Continuity’s SaaS platform uses Open Data and AI to detect insurance contracts that are either outdated or invalid across four product lines including Professional Indemnity, Commercial Property, Construction Workers Insurance, and Directors & Officers Liability.
LAfricaMobile
Series A in 2024
LAfricaMobile is a digital multichannel cloud communication platform based in Dakar, Senegal, founded in 2014. The company focuses on facilitating communication between enterprises in Africa and their customers, including those in the diaspora. By offering customized mobile marketing solutions that consider the local context, LAfricaMobile enhances the interaction between businesses and their clientele. Its platform specializes in mobile messaging interconnection and integration services, enabling companies to reach a broad audience effectively. This adaptability across multiple operators, channels, and countries ensures that end consumers have instant, secure access to the information they require, thereby strengthening customer relationships in the African market.
Biodol Therapeutics
Grant in 2024
Biodol Therapeutics, founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. New findings from Biodol Therapeutics' academic partnership (Cyril Rivat and Jean Valmier at the INSERM Institute for Neurosciences in Montpellier) also demonstrated that FLT3 inhibition increases the potency of opioids for their analgesic effect, and hereby reduces their safety risks, especially addiction risk, which will help fighting the Opioid Crisis. The development of extracellular inhibitors of the FLT3 receptor, is a proprietary and key approach developed by Biodol Therapeutics.
Eyco
Series A in 2024
Eyco specializes in designing and manufacturing smart circuits, playing a significant role in the European microelectronics sector. The company produces hardware components for digital applications, focusing on high-tech solutions that operate with minimal environmental impact. Eyco's commitment to sustainable practices enables clients to implement secure digital applications while promoting environmentally friendly manufacturing processes. Through its advanced industrial machinery, Eyco ensures efficient mass production tailored to client specifications, contributing to the evolving landscape of electronics.
Magnetfab
Grant in 2024
Magnetfab pioneers the mass-production of integrated micromagnets, driving advanced miniaturization for next-generation consumer electronics, robotics, quantum computing, and beyond.
Ascendance
Funding Round in 2024
Founded in 2018 by four ex-Airbus engineers: Jean-Christophe Lambert, Thibault Baldivia, Clément Dinel and Benoît Ferran, Ascendance is an industrial start-up with a mission to decarbonise aviation. Based in the heart of Toulouse, the European capital of aviation, it has developed and markets two products: an innovative hybrid-electric propulsion system ‘Sterna’, and a hybrid-electic vertical take-off and landing (VTOL) aircraft powered by Sterna technology, ‘Atea’.
Tribun Health
Grant in 2024
Tribun Health specializes in developing diagnostic imaging software aimed at enhancing cancer detection and diagnosis. The company offers innovative solutions that facilitate the digital transformation of cancer diagnostics, enabling diagnostic laboratories and pharmaceutical and biotech businesses to manage, analyze, and share cellular images effectively. By providing advanced tools for digital microscopy-like image analysis and macroscopic imaging, Tribun Health ensures accurate diagnostics and scientific evaluations of patient cell and tissue images, contributing to improved healthcare outcomes in oncology.
SeaBeLife
Grant in 2024
SeaBeLife is a biotechnology company that develops a range of drug candidates intended to block regulated necrosis (or regulated cell death of cells), from a family of patented molecules.
Surge
Grant in 2024
Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.
Sequans Communications
Grant in 2024
Sequans Communications S.A. (NYSE: SQNS) is a 4G chipmaker and leading provider of single-mode LTE chipset solutions to wireless device manufacturers worldwide. Founded in 2003, Sequans has developed and delivered seven generations of 4G technology and its chips are certified and shipping in 4G networks around the world. Today, Sequans offers two LTE product lines: StreamrichLTE™, optimized for feature-rich mobile computing and home/portable router devices, and StreamliteLTE™, optimized for M2M devices and other connected devices for the Internet of Things. Sequans is based in Paris, France with additional offices in the United States, United Kingdom, Israel, Hong Kong, Singapore, Taiwan, South Korea, and China.
Hawkcell
Series A in 2024
HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.
Sunver
Grant in 2024
Sunver is a start-up offering the first fully plug & play B2B SaaS solution for tourism establishments and restaurants, enabling them to create and configure a Guest App in just a few minutes.
UniFox
Grant in 2024
UniFox is an AI-driven ecosystem focused on sustainable investment, integrating green energy and eco-responsible technologies for individual and institutional investors. Its structure encompasses four divisions: B2C, B2B, Capital Ventures, and Green DeFi. Central to its offerings is VulpesAI, a multi-modal AI engine that employs market data, sentiment analysis, and ESG (Environmental, Social, Governance) criteria to create optimized investment strategies while operating on renewable energy sources. For individual users, UniFox provides AI-powered portfolio management that delivers comprehensive market insights and risk management, allowing for personalized investment strategies. On the institutional side, it offers advanced data access and metrics for large-scale investments in green projects. The Green DeFi division focuses on financing eco-friendly technology initiatives through decentralized finance, utilizing eco-taxed products and tokens to support sustainable ventures. Overall, UniFox seeks to enhance the accessibility of investment opportunities while promoting environmental responsibility and addressing challenges faced by novice traders in the market.
Groover
Series A in 2024
Groover is a comprehensive music promotion platform designed for independent artists, serving a community of 200,000 users across more than 186 countries. The platform allows artists to easily and directly submit their music to a network of media outlets, radio stations, playlists, and labels. Through this service, musicians can receive quality feedback and concrete sharing proposals from a vetted community of 3,000 music curators and professionals. With over two million pieces of feedback provided on submitted tracks, Groover aims to enhance the promotion and discovery of music for independent artists, ensuring they gain honest insights and increased visibility based on their performances.
Greenerwave
Series A in 2024
We are aiming to change the world by helping every customer to always have a good wireless indoor connection
Panopli
Series A in 2024
Panopli is an online platform based in Saint-Ouen, France, that specializes in the customization and management of personalized gifts and team apparel. Founded in 2017, the company offers a range of artistic items, including clothing such as t-shirts and sweaters, as well as decorative pieces like art posters and drawings. Panopli's service simplifies the gifting process by allowing customers to browse and purchase unique items, which are then shipped directly to the recipient. The platform also provides order tracking and inventory management, ensuring a seamless experience for users looking to send thoughtful gifts without the hassle of traditional gifting methods.
AQEMIA
Series A in 2024
AQEMIA is a pharmatech company focused on drug discovery, utilizing a platform that integrates machine learning with quantum-inspired physics. This innovative approach allows for the efficient identification of new drug candidates aimed at specific therapeutic targets. By employing advanced algorithms, AQEMIA's platform is capable of predicting the interactions and affinities between potential drug molecules and their targets. This methodology not only accelerates the drug discovery process but also contributes to a growing pipeline of viable drug candidates for various medical applications.
Aldoria
Series A in 2024
Aldoria specializes in space situational awareness, focusing on the collection, processing, and utilization of data to protect critical assets in space. The company addresses the growing challenges of space sustainability caused by increasing amounts of space debris and traffic. Its services encompass the detection, tracking, cataloging, and risk assessment of artificial satellites and space debris. By actively monitoring these elements, Aldoria helps operators and space organizations avoid potential hazards and adjust orbital paths, ultimately contributing to safer and more sustainable space operations. The company also provides users with a modern situational awareness platform and detailed sustainability reports.
Temo
Series A in 2024
Temo specializes in the manufacturing of portable electric motors designed for small watercraft, including dinghies, sailing boats, and rowboats. The company's products are characterized by their lightweight design and ease of installation, allowing users to enhance their boating experience with efficient outboard electric propulsion systems. By focusing on user-friendly solutions, Temo aims to meet the needs of recreational boaters seeking reliable and convenient alternatives to traditional motor systems.
I.Ceram
Grant in 2024
I.Ceram SA, founded in 2005 and based in Limoges, France, specializes in the design, manufacture, and marketing of alumina bio-ceramic implants. The company produces implants for various joints of the human body, including the ankle, knee, hip, spine, shoulder, wrist, skull, tibia, and foot. In addition to joint implants, I.Ceram also offers osteosynthesis products. As a subsidiary of Investissement Développement, I.Ceram operates both domestically and internationally, focusing on high-tech solutions in the medical implant sector.
Okomera
Grant in 2023
Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.
Novacium
Grant in 2023
Novacium operates as an innovative start-up that specializes in the next generation material development.
eyeGauge
Grant in 2023
eyeGauge is a Paris-based deep tech start-up dedicated to transforming the maritime industry by facilitating the decarbonization of maritime transportation. The company aims to help shipping companies meet International Maritime Organization targets by reducing greenhouse gas emissions by at least 50% by 2050. To comply with decarbonization regulations, ship owners must accurately measure and report emissions after every voyage. However, 85% of the world's fleet currently relies on manual data collection, which is often unreliable and difficult to analyze. eyeGauge addresses this challenge by offering an innovative, automated solution that collects data from onboard systems in a contactless and non-invasive manner. This technology generates consistent and comparable data, creating a digital model of a vessel's equipment and machinery. By providing insights into operations, eyeGauge enables shipping companies to identify optimization opportunities and enhance efficiency, ultimately supporting their efforts to reduce emissions and comply with regulations.
Prove & Run
Series A in 2023
Prove & Run has been created with the idea that large scale deployment of connected objects will become a target for remote cyber-attacks and that the technologies in use in the mobile industry were insufficient to answer to the challenge. When designing connected objects, security engineers can in effect rely on three pillars: (1) Secure elements or hardware coprocessors; (2) Trusted Execution Environment (TEE) or secure OSs; (3) Hardware - or software-based hypervisors. In order to resist to sophisticated remote attacks, the last two need to be formally proven so as to be as close as possible to zero-bugs. This is what we have done at Prove & Run with ProvenCore, a formally proven secure OS and ProvenVisor a next generation secure hypervisor. In most cases using of single instance of ProvenCore on a given connected object will be sufficient to protect against hackers with multi-million dollar budgets.
Astraveus
Grant in 2023
Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.
Poppins
Venture Round in 2023
Poppins merges music, technology, and neuroscience to reshape therapy into a musical experience. We create musical games for children based on neurologic music therapy methods. These games are designed to address learning dissabilities like dyslexia, providing a digital treatment at home and helping identify these conditions. Behind these games, we leverage data science and new technologies to interpret learning, language, and motor performance into a cognitive score. Our goal is to improve the process for patients receiving treatment and to reaching the vast undiagnosed majority.
Injectpower
Grant in 2023
Injectpower creates energy storage technologies and micro-batteries for medical implants. Its small solid-state battery allows devices to function as sensors or actuators, collecting data continuously and autonomously for weeks without needing to be recharged. Their micro-batteries, which have been developed over 16 years and have 40 patents, are manufactured utilizing a verified semiconductor supply chain and have high reliability.
Hughy
Grant in 2023
F&B advertising webapp
Albert
Venture Round in 2023
Albert is a software company that provides a SaaS platform. The company was founded in 2018 and is based in Paris, France.
Spark Cleantech
Grant in 2023
Spark is pioneering a novel method of producing hydrogen: methane plasmalysis, which uses less electricity and has a long carbon sequestration. Plasma discharges are used to power the methane plasmalysis: electrons are produced, accelerated, and hit with methane molecules to disintegrate them.
Niryo
Series A in 2023
Niryo is a provider of educational robots intended to help in prototype industrial case studies.
Global Bioenergies
Grant in 2023
Global Bioenergies is one of the few companies worldwide, and the only one in Europe, that is developing a process to convert renewable resources into hydrocarbons through fermentation. The Company initially focused its efforts on the production of isobutene, one of the most important petrochemical building blocks that can be converted into fuels, plastics, organic glass and elastomers. Global Bioenergies continues to improve the performances of its process, operates an industrial pilot, is completing the construction of its demo plant in Germany, and is preparing its first full-scale plant through a Joint-Venture with Cristal Union, named IBN-One. The company also replicated its achievement to propylene and butadiene, two members of the gaseous olefins family, key molecules at the heart of petrochemical industry. Global Bioenergies is listed on Alternext, Euronext Paris (FR0011052257 – ALGBE).
Umiami
Series A in 2023
Umiami is a French food-tech startup founded in 2020 and based in Paris, focused on developing plant-based food technology aimed at reducing meat consumption. The company specializes in creating plant-based whole-cuts that utilize plant proteins, providing consumers with alternatives that closely replicate the taste, texture, and aroma of traditional meat products. By offering these innovative solutions, Umiami seeks to address the growing demand for sustainable food options while promoting healthier dietary choices.
Circul'Egg
Grant in 2023
Circul'Egg recycles the eggshells from companies by transforming them into two finished products: a calcium carbonate powder and a shell membrane powder. It promotes industrial co-products in the circular economy. The company's products are marketable on the animal feed and nutraceutical markets. This production responds to a need expressed by many players in animal feed (PetFood and feed for farm animals), nutraceuticals (food supplements for human consumption), and cosmetics. It was established in Paris, Ile-de-France, France in
Remixt
Grant in 2023
Remixt is a leading Diversity, Equity and Inclusion tech platform dedicated to preventing key HR risks caused by harassment and discrimination. The company is headquartered in Paris, France, with employees in Paris, San Francisco, Toulouse and Annecy. Remixt’s clients include global corporations Heineken, Société Générale, Accenture, Groupe BPCE-Natixis and Hexagon. For more information: http://www.remixt.co
Eramet
Grant in 2023
ERAMET is a world leader in alloy metals, including manganese and nickel, and high-end metallurgy. ERAMET also develops activities with high growth potential, such as mineralized sands (titanium dioxide and zircon), lithium and recycling. The Group employs approximately 13,000 people in 20 countries.
Toopi Organics
Grant in 2023
Toopi Organics SAS is a biotechnology company based in Langon, France, that specializes in the collection and upcycling of human urine to create biostimulants for agriculture. Founded in 2019, the company develops products like Arbop and Vitip, which support plant growth by serving as natural alternatives to chemical fertilizers. Toopi Organics employs microbiological technology to enhance and enrich human urine, providing an environmentally friendly solution for the agricultural community. By transforming waste into valuable resources, the company aims to offer economical and efficient options for sustainable farming practices.
Teale
Series A in 2023
Teale is a digital mental health platform that integrates psychology and technology to enhance mental well-being. The platform offers personalized and interactive digital healthcare solutions, enabling individuals to manage their mental health effectively. Teale also conducts collective workshops tailored to specific needs within workplaces, fostering a supportive environment for mental health initiatives. Through its curated network of mental health experts, Teale provides individual support and personalized digital programs, allowing users to monitor and improve their psychological resilience. This approach not only benefits individuals but also contributes to sustainable growth for organizations.
Dattak
Series A in 2023
Dattak specializes in providing cyber insurance solutions that leverage advanced cybersecurity technologies. By utilizing these tools, Dattak enables businesses to assess their cybersecurity posture without the need for complex questionnaires. The company focuses on serving insurance brokers and clients, including veterinary specialists, emergency services, and small to medium-sized enterprises, by offering tailored cyber insurance options. Dattak's approach not only helps clients secure insurance coverage but also equips them with resources to effectively prevent and defend against cyberattacks, thereby reducing overall risk.
Mob-Energy
Series A in 2023
Mob-Energy is a privately held company founded in 2018 and based in Villeurbanne, Auvergne-Rhône-Alpes. The company specializes in developing innovative mobile charging solutions for electric vehicles. Its autonomous charging robots are designed to optimize existing infrastructure by storing energy in second-life batteries installed in parking facilities. These robots can autonomously move to vehicles that request a charge, providing a convenient and efficient way for clients to power their parked cars. Through its technology, Mob-Energy aims to enhance the accessibility and usability of electric vehicle charging systems.
SFE PROCESS
Series A in 2023
SFE PROCESS designs and manufactures lab equipment.
Santexpat.fr
Series A in 2023
Santexpat is a health insurance platform for French expatriates in more than 200 countries. It allows users to analyze more than 100 health insurance solutions and subscribe to them directly. The company also offers teleconsultations with French-speaking doctors 24/7. Santexpat was founded in 2020 and is based in Paris, France.
Cleyrop
Series A in 2023
Cleyrop provides a secure data hub that simplifies access and enhances the use of data for its clients. The company offers a comprehensive portal and a scalable application suite designed to ingest, store, process, exploit, and visualize data efficiently. Key features include collaborative workspaces, management of access rights and security, and oversight of storage and computing infrastructures. Additionally, Cleyrop enables the deployment and orchestration of data pipelines, as well as the viewing and sharing of data stories. This suite empowers clients to govern, catalog, supervise, and monitor their data assets in a secure and industrial environment, ensuring effective data management and accessibility.
Santé Académie
Series A in 2023
Santé Académie is an online training platform focused on providing continuous medical education to healthcare professionals. Recognizing the evolving roles of caregivers and the rapid obsolescence of medical knowledge, the platform offers high-quality educational videos tailored to the schedules of busy professionals. Each course is divided into short episodes ranging from 5 to 15 minutes, allowing doctors, nurses, pharmacists, and care assistants to learn at their own pace. The courses cover clinical and regulatory topics and are certified by the ANDPC, produced by experts from prestigious institutions. With the aim of enhancing patient care and engagement, Santé Académie has already gained approval from over 20,000 professionals and health institutions, making advanced medical knowledge accessible directly from mobile devices.
Deemea
Grant in 2023
Deemea is a developer of a digital medical assistance platform tailored for clinical research and the analysis of real-life data. The company's AI-driven platform assists clinical research operators by streamlining the imaging data journey, enhancing efficiency and reliability. It utilizes artificial intelligence to identify suitable databases, expedites contractual and regulatory processes, and simplifies external model validation. Additionally, Deemea's platform optimizes responses to internal and external requests while valorizing real-world data and clinical studies. Through these capabilities, Deemea supports clients in accelerating the development and deployment of innovative projects that leverage AI tools specific to the valorization of medical data.
EyeLights
Series A in 2023
EyeLights specializes in innovative motorcycle accessories by offering a Head Up Display GPS that enhances rider safety and experience. This device projects crucial navigation and safety information directly into the rider's line of sight, allowing them to maintain focus on the road. It alerts users to potential hazards such as dangerous bends, nearby obstacles, and speed limit violations. Designed for quick installation on various types of helmets, the EyeLights product can be set up in under five minutes. Its compact optical technology ensures visibility of GPS data from over two meters away and supports audio functions for up to eight hours. The device is adaptable to sun visors, resistant to rain and fog, and lightweight, weighing less than 100 grams, making it a practical choice for motorcycle enthusiasts seeking enhanced situational awareness while riding.
Kiro
Series A in 2023
Operator of a digital medicine company intended to provide insights on laboratory test results that are understandable to patients. The company fosters the interactions between laboratories, health professionals and patients and goes beyond results in patient care through the use of new technologies and artificial intelligence, enabling medical professionals to easily interpret and diagnose in a personalized and effective way.
XXII
Series A in 2023
XXII is a technology company with over 50 employees that specializes in the design, development, and marketing of a SaaS platform known as XXIICORE. This platform is focused on deploying and configuring algorithms specifically for video stream analysis. XXII's solution has gained traction among various sectors and local authorities, enabling users to leverage video analysis to enhance operational performance. Clients benefit from the ability to create new tools and applications using the company’s algorithms, which facilitate real-time video analysis and offer measurable advantages in their operations.
Kovalee
Series A in 2023
Kovalee is a mobile app publisher that supports app creators by providing a comprehensive application publishing platform. The company partners with app owners to elevate their apps in the marketplace, offering services such as product enhancement, user acquisition, monetization, and app store optimization. Kovalee's platform features modular design and application testing, enabling developers to focus on content and code while leveraging data-driven strategies. Additionally, the company employs artificial intelligence to predict customer behavior, helping developers optimize their apps for better performance and profitability.
AlgoTherapeutix
Grant in 2023
AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.
Pili
Series A in 2023
PILI Inc. is a company based in Paris, France, that specializes in researching and manufacturing bio-fabricated colors derived from microorganisms. Founded in 2012, the company focuses on designing enzymes and fermentation biotechnologies that convert sugar into sustainable and long-lasting dyes and pigments. PILI produces renewable inks as an eco-friendly alternative to traditional toxic and non-recyclable options. The company emerged from a collaboration among a biologist, a designer, and a financial analyst in a biohacker space, leading to the creation of innovative products like a pen fed by bacteria. By utilizing microorganisms, PILI aims to replace petrochemical and non-sustainable vegetable dyes, promoting sustainable development while also helping businesses reduce costs.
Oneleaf
Grant in 2023
Oneleaf is a startup that seeks to make hypnosis more widely available. It has created an app to assist people in getting started with hypnosis and following various programs to help them quit smoking, reduce anxiety, or lose weight. Their objective is to use self-hypnosis to help a billion individuals become the finest versions of themselves.
NFL Biosciences
Grant in 2023
NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.
Miraxess
Venture Round in 2023
Miraxess specializes in transforming smartphones into functional laptops through its innovative product, the Mirabook. Recognizing the growing reliance on smartphones for personal and professional tasks, the company has developed a plug-in device that enhances the capabilities of mobile phones, effectively creating a full-fledged laptop experience. This solution aims to improve productivity and comfort, catering to the needs of users for both work and entertainment. By leveraging the existing power of smartphones, Miraxess offers a practical convergence of mobile and computing technology.
Ervaccine Technologies
Series A in 2023
ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.
Meelo
Series A in 2022
Meelo is a SaaS solution to facilitate, secure, and automate customer onboarding, fight against fraud and the risk of non-payment. It offers open data and AI to identify new customers and predict the behavior. It's a modular solution to fight against fraud and the risk of unpaid.
Axonaut
Series A in 2022
Axonaut is an online management software company founded by Nicolas Ricard on January 1, 2017, in Labège, Midi-Pyrenees. The software is designed specifically for small businesses, allowing them to automate various processes such as sales, costs, and taxes while managing accounting codes tailored to their needs. Axonaut provides a comprehensive suite of features, including customer relationship management, order creation with recurring subscription invoices, payment alerts, project allocation, and quote generation. This enables clients to centralize and efficiently manage all their business tasks on a single platform.
Remedee Labs
Series A in 2022
Remedee Labs SAS is a French company founded in 2016, specializing in the research and development of a personal endorphin stimulator aimed at pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a device designed to stimulate the release of the body’s own endorphins on demand. This innovative technology is particularly focused on helping individuals suffering from chronic pain conditions, with an initial emphasis on fibromyalgia. Remedee Labs has developed a patient-centered digital service platform that collaborates with medical practitioners to enhance chronic pain management. Backed by a decade of pre-clinical and clinical research, the company aims to provide a new approach to pain relief for the 1.5 billion people worldwide affected by chronic pain, many of whom are dissatisfied with existing treatment options. In 2019, Remedee Labs secured significant funding from various investors to further its mission of making endorphin-stimulation therapy accessible and effective for personal healthcare.
Ejara
Series A in 2022
Ejara is a mobile investment platform tailored for Africa and its diaspora, allowing users to access a variety of investment opportunities, including fractional shares, commodities, and cryptocurrencies. The app leverages blockchain technology to facilitate global trading and investment in diverse financial products. It also offers features such as interest-bearing accounts, enabling users to save and grow their wealth while monitoring their investment performance. By providing a user-friendly interface, Ejara aims to empower individuals to manage their investments effectively and enjoy greater financial independence.
Aniah
Series A in 2022
Aniah specializes in providing an integrated circuit (IC) verification tool designed to identify and rectify electrical errors in chip designs efficiently. The company's platform conducts a comprehensive analysis at the transistor level, ensuring that all potential power states are covered in a single run. This approach allows users to concentrate on genuine errors rather than sifting through false positives. Aniah's technology delivers relevant results within seconds, empowering engineers to enhance their designs continuously and expedite the sign-off process. By minimizing the risk of electrical errors early in the design phase, Aniah supports semiconductor projects and improves overall workflow efficiency for its clients.
Verkor
Funding Round in 2022
Verkor is a manufacturer of battery cells dedicated to producing low-carbon batteries to meet the rising demand for electric vehicles. The company emphasizes the development of batteries that have a significantly smaller carbon footprint compared to traditional options, which not only reduces overall emissions but also lowers logistics costs. By utilizing carbon-free electricity in its production processes, Verkor aims to provide businesses with affordable battery solutions that align with sustainability goals.
Jeudimerci
Series A in 2022
JeudiMerci is a marketing platform headquartered in Paris, France, that simplifies the process of sending physical gifts, comparable to sending an email. Founded in 2019, the company focuses on enhancing B2B customer experiences by automating the delivery of gifts at crucial points in the customer journey. Its services include both online and offline marketing solutions, which facilitate centralized gifting outreach to engage customers and employees effectively. By leveraging this platform, businesses can create meaningful connections with prospects and clients, ultimately driving brand engagement and development.
Shortcut
Grant in 2022
Shortcut supports CGPs and enables automation of emailing, invitations and customer communications.
Cuure
Series A in 2022
Cuure specializes in providing personalized vitamins and supplements tailored to individual health requirements. Utilizing data from health questionnaires and DNA tests, Cuure develops customized supplement plans aimed at enhancing overall health and wellness. Their offerings combine scientific research with a personalized approach, ensuring that users receive recommendations aligned with their specific health goals and body chemistry. Additionally, the platform promotes wellness habits through a tracking application, allowing individuals to monitor their supplement intake and adapt their health practices effectively. Cuure's commitment to fair pricing and personalized solutions makes it a distinctive player in the wellness industry.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.